StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Humira (adalimumab) — U.S. reported growth YoY by Year

Humira (adalimumab) — U.S. reported growth YoY (%) (%)

AbbVie Humira (adalimumab) — U.S. reported growth YoY: -57.1% in FY2025, down 15.8 pts from a year earlier. That is the lowest of the 9 years on record here.

Latest, FY2025
-57.1%
Period ended Dec 31, 2025
Change on a year earlier
-15.8 pts
-41.3% in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Humira | 3,062 | 1,478 | 4,540 | (57.1) | (20.2) | (49.5) | (19.5) | (49.4)”

Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). AbbVie Humira (adalimumab) — U.S. reported growth YoY (%), annual FY2017–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/humira-us-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.